Results: Twenty-three males and two females were enrolled in this study, and the mean age was 37 years. Baseline HBV DNA and ALT level were 5.94×106copies/mL and 73 IU/L respectively. And baseline HBsAg level was 2398IU/mL. By the end of 48 weeks of treatment, all patients (25/25) achieved a virological response, and maintained HBV DNA undetectable during the treatment period. HBsAg seroconversion rates were 12% after 48 weeks of treatment, rising to 28% after 96 weeks of treatment. Extended treatment to 96 weeks was well tolerated. The safety profile of 96 weeks of treatment was similar to that seen in patients treated for 48 weeks. |